This study aims to describe the patient population treated and the real-life patients' experiences with Xamiol®gel in the long term, up to 52 weeks management of body psoriasis vulgaris in Russia. The result will increase the knowledge on Xamiol®gel enabling dermatologists and patients to optimize its use in the long term management of psoriasis.

Inclusion Criteria:

• Psoriasis vulgaris on body
• Patients planned to receive topical treatment on the body with calcipotriol/betamethasone gel
• Written informed consent

Exclusion Criteria:

• No or very mild symptoms of psoriasis vulgaris on the body at study start
• Any on-going treatments at study start with topical steroids, salicylic acid or its combination
• Other topical treatment for body psoriasis
• Pregnancy or planned pregnancy within treatment period
• Contraindications according to prescribing information.

Patients diagnosed with body psoriasis who (at their physician's discretion) are eligible to receive topical treatment with calcipotriol/betamethasone gel